Where it trades today
trading 50% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- BAX carries a beta of 0.59, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- BAX remains in a bearish short-term trend and sits 24.0% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- BAX is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for BAX come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for BAX. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Baxter International does
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision…
Employees
37,500
Industry
Medical Instruments & Supplies
Headquarters
Deerfield, United States
What analysts expect
BAX carries a hold consensus from 11 analysts, with an average price target of $28.73 versus $22.80 today (+26.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BAX generated $11.47B in trailing revenue (5.3% year over year), with a -9.3% net margin, and $1.00B of free cash flow, against $7.52B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $11.24B | $3.38B | $177.00M | -$957.00M | -$1.87 | $323.00M |
| 2024 | $10.64B | $3.98B | $439.00M | -$649.00M | -$1.27 | $559.00M |
| 2023 | $10.36B | $4.15B | $707.00M | $2.66B | $5.25 | $1.29B |
| 2022 | $10.06B | $3.55B | -$33.00M | -$2.43B | -$4.83 | $576.00M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
BAX beside the healthcare names it is usually measured against.
What the chart is saying
Baxter International trades at $22.80, 24.0% below its 52-week high. With a beta of 0.59, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is BAX a good buy right now?
Baxter International operates in the Healthcare sector. Current risk level is Medium based on 21.8% volatility.
Does BAX pay dividends?
Yes, Baxter International offers a dividend yield of 0.17%. That is roughly $0.04 per share a year.
How volatile is BAX?
With 30-day annualized volatility of 21.8% and beta of 0.59, BAX is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for BAX?
The average analyst price target for Baxter International (BAX) is $28.73 based on 11 analyst estimates, about 26.0% above the current price of $22.80. The published range runs from $23.00 to $40.00.
How much revenue does BAX generate?
Baxter International reported $11.47B in trailing twelve-month revenue. Revenue growth is running at 5.3% year over year. Net margin sits at -9.3%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.